learn PP405
mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials
Search
forLearn
5 / 27 resultslearn Osteopontin
signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss
learn Latanoprost
glaucoma medication with hair follicle stimulant effects
learn Hair Multiplication
extract, clone, and reinsert your own hair cells
learn Overview
Research
5 / 1000+ results
research Fatigue, Alopecia, and Stomatitis Among Patients With Breast Cancer Receiving Cyclin-Dependent Kinase 4 and 6 Inhibitors: A Systematic Review and Meta-Analysis
Breast cancer patients taking CDK4/6 inhibitors are more likely to experience fatigue, hair loss, and mouth sores.
research An Antifungal for Antidiuresis? Fluconazole's Potential in Treating Nephrogenic Diabetes Insipidus
Fluconazole might be a new treatment for a type of diabetes that affects water balance in the body.
research Therapeutics for COVID-19 and Post COVID-19 Complications: An Update
New treatments for COVID-19 show promise, but more effective antiviral drugs are needed.
research Plucked Human Hair Shafts and Biomolecular Medical Research
Human hair follicles may provide a noninvasive way to diagnose diseases and have potential in regenerative medicine.
research Androgen Deprivation Therapy in Prostate Cancer: Focusing on Sexual Side Effects
Androgen Deprivation Therapy for prostate cancer often reduces sexual function but intermittent therapy may be more tolerable.
Community Join
5 / 1000+ resultscommunity Is there any word on when Stempsen Therapeutics and Hairclone will start phase 1 clinical trials?
Hair cloning trials by Stempsen Therapeutics and Hairclone have no updates, and it may take at least 15 years for hair cloning to be available. The conversation also mentions treatments like Minoxidil, finasteride, and RU58841.
community Looks like Kintor finished enrollment and dosing of phase 1 for gt20029 in China.
The conversation discusses the potential of a new hair loss treatment, GT20029, which targets androgen receptors in the scalp and is in phase 1 trials in China. Users express hope that this treatment will be more effective than current options like Minoxidil and Finasteride.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community What ever happened to pyrilutamide?
Pyrilutamide, a potentially effective hair loss treatment; other topical treatments like RU58841 and CB-03-01 that may have fewer side effects than Pyrilutamide; and the Phase 3 clinical trials of Pyrilutamide, which is likely to be approved by the FDA soon.
community The Cure isn't 5 years away; it's already here.
PP405 is a new topical treatment for hair loss, showing promise in trials but still requires finasteride for maintenance. There is skepticism about its effectiveness and safety, with concerns about needing finasteride to maintain results.